Patents by Inventor Volker MORATH

Volker MORATH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOORTHOGONAL REPORTER GENE SYSTEM
    Publication number: 20230365636
    Abstract: The present invention relates to a nucleic acid molecule encoding a fusion protein comprising (i) a secretory signal peptide; (ii) a lipocalin-derived binding protein specifically binding to an exogenous ligand; and (iii) a glycosylphosphatidylinositol (GPI) anchored and/or transmembrane domain.
    Type: Application
    Filed: November 16, 2021
    Publication date: November 16, 2023
    Inventors: Volker MORATH, Arne SKERRA, Wolfgang WEBER, Katja FRITSCHLE
  • PSMA-specific binding proteins
    Patent number: 11464877
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: October 11, 2022
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98hc
    Publication number: 20220153790
    Abstract: The present invention relates to a cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein, wherein the CD98hc-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to CD98hc with a KD of 200 nM or lower.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 19, 2022
    Inventors: Arne SKERRA, Friedrich-Christian DEUSCHLE, André SCHIEFNER, Volker MORATH
  • NOVEL PSMA-SPECIFIC BINDING PROTEINS
    Publication number: 20200038523
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 17, 2019
    Publication date: February 6, 2020
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • PSMA-specific binding proteins
    Patent number: 10406247
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: September 10, 2019
    Assignees: Technische Universität München, Biotechnologicky Ustav AV CR, v.v.i.
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • NOVEL PSMA-SPECIFIC BINDING PROTEINS
    Publication number: 20180318451
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 6, 2016
    Publication date: November 8, 2018
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne SKERRA, Antonia RICHTER, Volker MORATH, Cyril BARINKA, Jakub PTACEK